0.5 CME Credits. This webinar is a 30-minute overview of psychological and psychodynamic factors that can impact the psychopharmacological treatment of patients.
0.5 CME Credits. This webinar is a comprehensive 30-minute overview of psychodynamic principles, processes, and evolution for mental health professionals.
0.75 CME Credits. This webinar discusses ADHD and its varied presentations, co-occurring issues, and the importance of accurate assessment for effective treatment.
0.25 CME Credits. In this episode, we explore nine groundbreaking stories in mental health and psychiatric medicine, covering everything from healthcare fraud to the latest advancements in drug trials. First, we dive into the recent charges brought by the US Department of Justice against executives at Done, a California-based telehealth company, for alleged healthcare fraud. Done is accused of prescribing over 40 million Adderall pills to patients without proper evaluation, raising concerns about the balance between increasing mental healthcare access and responsible prescribing practices.
Prescribing stimulants outside of ADHD is not illegal, but what Done did sent the clinical leader to jail. We look at what went wrong and what the charges were, and end with a research update that improves access to psychiatric care the honest way.
A Silicon Valley founder built a telehealth company to make ADHD treatment as easy as ordering takeout, until federal prosecutors traced 37 million pills of Adderall back to the clinic. We follow Done from venture-backed startup to criminal conviction, and ask what the case means for how we diagnose and treats ADHD. Plus: a new FDA approval adds a third option to the ADHD reuptake-inhibitor family.
A Silicon Valley founder built a telehealth company to make ADHD treatment as easy as ordering takeout, until federal prosecutors traced 37 million pills of Adderall back to the clinic. We follow Done from venture-backed startup to criminal conviction, and ask what the case means for how we diagnose and treats ADHD. Plus: a new FDA approval adds a third option to the ADHD reuptake-inhibitor family.
Today, we’re tackling a deceptively simple question that comes up all the time in clinical practice: When should we prioritize medication, when should we emphasize psychotherapy, and when can we recommend both? This question comes up especially often with patients who are new to treatment. They’ll ask, “Do I need a medication?” or “Can I just do therapy?” And while it’s tempting to answer in generalities, the evidence actually gives us much clearer guidelines, depending on the substance that the patient is using.
It's easy to see why this case has captured so much attention. The legal question alone is complicated, but the case leaves clinicians with harder questions to sit with: “Would I recognize postpartum psychosis if it showed up in my practice? Would I have caught it?” Probably not every time, if we’re honest.
Dr. Chris Aiken and Kellie Newsome, PMHNP have covered lithium quite a bit on The Carlat Psychiatry Podcast. Are you up to date on this cornerstone of psychiatry? Here's a clearinghouse of lithium episodes to catch you up.
Five free episodes on the issues that matter most in child and adolescent psychiatry today — from suicide risk in autistic youth to anxiety, sleep, legal systems, and expanding access to care. Hosted by Dr. Joshua Feder and Mara Goverman, LCSW.
For 23 years, Dr. Carlat and his team of clinical experts have developed a mountain of peer-reviewed articles and books covering almost every aspect of psychiatry. Unlike many journals, these resources are straightforward, plain spoken, and actionable for the everyday work clinicians face. This year we took that massive archive and put it to work for you in a brand new interface called AskCarlat AI.
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.webp?t=1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
